Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 24, 2024

OSR Holdings, SillaJen sign MoU to pursue drug development

Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.

Continue
The companies will leverage shared technology as well as clinical development resources to create synergies in therapeutics development. Credit: Louis Reed/Unsplash.
April 22, 2024

Merck’s PREVYMIS gets Health Canada’s approval for CMV disease prevention

The latest approval was based on the results of a Phase III, double-blind, multi-centre, randomised, active comparator-controlled non-inferiority trial. Credit: Robina Weermeijer/Unsplash.
April 19, 2024

SK pharmteco signs agreement to manufacture Ferring’s ADSTILADRIN

Ferring’s ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy. Credit: Furiosa-L from Pixabay.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Popular

  1. BMS to boost CAR T cell therapy production with Cellares deal
  2. Orladeyo gains approval in Brazil for HAE prevention
  3. Telix Pharmaceuticals secures FDA fast track status for TLX101-CDx
  4. Immuno-oncology company Portage Biotech to evaluate strategic alternatives
  5. NICE recommends Novartis’ CAR-T therapy for leukaemia

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation